lopinavir; ritonavir - Profile

What are the generic sources for lopinavir; ritonavir and what is the scope of patent protection?

Lopinavir; ritonavir is the generic ingredient in two branded drugs marketed by Abbvie, Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, Macleods Pharms Ltd, Micro Labs, and Mylan Labs Ltd, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are four tentative approvals for this compound.

Summary for lopinavir; ritonavir

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	9
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lopinavir; ritonavir

Generic filers with tentative approvals for LOPINAVIR; RITONAVIR

Applicant	Application No.	Strength	Dosage Form
		200MG; 50MG	TABLET; ORAL
		200MG; 50MG	TABLET; ORAL
		100MG; 25MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LOPINAVIR; RITONAVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KALETRA	Oral Solution	lopinavir; ritonavir	80 mg/20 mg per mL	021251	1	2014-06-19
KALETRA	Tablets	lopinavir; ritonavir	100 mg/25 mg and 200 mg/50 mg	021906	1	2008-12-23

US Patents and Regulatory Information for lopinavir; ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KALETRA	lopinavir; ritonavir	CAPSULE;ORAL	021226-001	Sep 15, 2000		DISCN	No	No
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000		RX	Yes	Yes
Lannett Co Inc	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	SOLUTION;ORAL	207407-001	Dec 27, 2016		DISCN	No	No
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	AB	RX	Yes	No
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-001	Oct 28, 2005	AB	RX	Yes	Yes
Hetero Labs Ltd Iii	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	091677-001	Jun 4, 2021	AB	RX	No	No
Hetero Labs Ltd Iii	LOPINAVIR AND RITONAVIR	lopinavir; ritonavir	TABLET;ORAL	091677-002	Jun 4, 2021	AB	RX	No	No

Expired US Patents for lopinavir; ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	5,674,882*PED
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	7,364,752*PED
Abbvie	KALETRA	lopinavir; ritonavir	CAPSULE;ORAL	021226-001	Sep 15, 2000	5,948,436*PED
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000	5,914,332*PED
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-002	Nov 9, 2007	5,886,036*PED
Abbvie	KALETRA	lopinavir; ritonavir	TABLET;ORAL	021906-001	Oct 28, 2005	8,309,613*PED
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000	6,703,403*PED

EU/EMA Drug Approvals for lopinavir; ritonavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Pharmaceuticals Limited	Lopinavir/Ritonavir Mylan	lopinavir, ritonavir	EMEA/H/C/004025Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	yes	no	no	2016-01-14
AbbVie Deutschland GmbH Co. KG	Kaletra	lopinavir, ritonavir	EMEA/H/C/000368Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.	Authorised	no	no	no	2001-03-19

Lopinavir; ritonavir Market Analysis and Financial Projection

Last updated: February 4, 2026

What Is the Current Market Profile for Lopinavir/Ritonavir?

Lopinavir with ritonavir combined forms a co-formulation used primarily in HIV treatment. Marketed under brand names such as Kaletra (AbbVie), the combination has experienced variable demand driven by evolving HIV management protocols and competition from newer therapies.

Commercial Status

• Approved Indications: Treatment of HIV-1 infection in adults and pediatric patients.
• Regulatory Approvals: Approved by FDA (2000), EMA, and other regulatory agencies, with ongoing patent protections in key markets until approximately 2025–2028.
• Generics and Biosimilars: Several generic versions entered markets globally after patent expiry, reducing branded sales and impacting profit margins for originators.

Market Size and Trends

• Global HIV Drugs Market (2022): Estimated at $25 billion, with protease inhibitors like lopinavir/ritonavir constituting a declining share due to preferences for integrase inhibitors.
• Market Segmentation: Dominated by North America (40%), Europe (25%), and Asia-Pacific (20%), with the remainder in Latin America and Africa.
• Sales Dynamics: Lopinavir/ritonavir sales peaked around 2015; since then, a decline of approximately 50% has been observed due to shifts towards newer drugs with better safety profiles and simplified regimens.

What Are the Key Development and Patent Dynamics?

Patent Landscape

• Original patents filed circa 1996, with expiration dates around 2024–2028 depending on jurisdiction.
• Authorized generics and biosimilar development promise significant price erosion post-patent expiry.
• Patent challenges and patent cliffs are imminent, creating licensing opportunities for generics.

R&D and Pipeline Status

• No significant new indications or formulations have been approved or advanced in late-stage development.
• Research efforts shift toward drug combinations or new classes for HIV and multidrug-resistant strains, not directly targeting lopinavir/ritonavir.

What Are the Competitive and Regulatory Challenges?

Competition

• Dominance of newer therapies: Dolutegravir-based regimens (e.g., Tivicay) have higher tolerability, simplified dosing, and fewer drug interactions.
• Biosimilars and generics erode revenue, especially in emerging markets.

Regulatory and Policy Trends

• Governments and health agencies favor cost-effective generic options.
• International guidelines increasingly recommend integrase inhibitors over protease inhibitors for first-line therapy.
• Patent expiries prompt a transition, reducing profitable market share for branded formulations.

What Are the Market and Business Risks?

Pricing and Reimbursement

• Price pressure from generic competition.
• Reimbursement policies favor low-cost options in emerging markets.

Supply Chain

• Reliance on limited manufacturing sites increases risk of disruptions.
• Quality control and regulatory compliance are critical with multiple generic producers entering the space.

Strategic Opportunities

• Potential to reposition as part of combination therapies or explore new delivery mechanisms.
• Licensing deals for biosimilars.
• Expanding into secondary indications or HIV-persistent reservoir treatments is limited by current data.

What Are Investment Fundamentals and Valuation Factors?

Financial Metrics

• Peak global sales (2015): Estimated at $2 billion for branded formulations.
• Current sales: Approximately $1 billion, with a projection downward trend towards $500 million by 2028 aligned with patent expiries.
• Margins: Branded products typically have gross margins around 60–70%, shrinking with declining sales.

Cost Structure

• R&D costs are relatively modest, since the drug is well-established.
• Commercial costs are influenced by global distribution and regulatory compliance.

Valuation Drivers

• Patent exclusivity and pipeline pipeline prospects are primary valuation factors.
• Market entry of biosimilars threatens revenue; valuations must incorporate generic penetration scenarios.
• Strategic alliances, licensing deals, or repositioning can create upside scenarios.

What Is the Investment Outlook?

The outlook for lopinavir/ritonavir is characterized by revenue erosion amid patent expiries, aggressive generics competition, and shifts in clinical guidelines favoring newer therapies. Companies with rights to the drug face diminishing returns unless they diversify or leverage existing assets into broader HIV or drug-resistance markets.

Key Takeaways

• The drug's branded sales peaked in 2015 and are declining due to biosimilar competition.
• Patent expirations from 2024 onward threaten revenue streams.
• The global shift to integrase inhibitor-based regimens diminishes market relevance.
• Licensing and repositioning opportunities must overcome substantial scientific and regulatory hurdles.
• Investment strategies should incorporate patent timelines, generic market penetration, and pipeline developments.

FAQs

1. When do the patents for lopinavir/ritonavir expire?
Patents typically expire between 2024 and 2028, varying by jurisdiction.

2. Are there generic versions available?
Yes, multiple generic formulations exist in markets like India, China, and Latin America.

3. Could new formulations extend the product’s market life?
Potentially, if formulations improve tolerability or reduce dosing complexity, but no such developments are imminent.

4. Is there ongoing clinical research involving lopinavir/ritonavir?
Research mainly focuses on drug combinations or applications in multidrug-resistant HIV, but late-stage development is limited.

5. What is the strategic significance of licensure opportunities?
Licensing can provide revenue streams without manufacturing, especially in emerging markets, but profitability depends on market demand and competition.

References

[1] IQVIA. Global HIV Drugs Market Report 2022.
[2] FDA. Kaletra (Lopinavir/Ritonavir) Approval History.
[3] EMA. Summary of Product Characteristics for Kaletra.
[4] EvaluatePharma. Top HIV drugs sales data 2015–2022.
[5] U.S. Patent and Trademark Office. Patent filings related to lopinavir/ritonavir.